Cardiac amyloidosis imaging and diagnosis
Research activity centres on ATTR cardiac amyloidosis and AL cardiac amyloidosis, with a strong focus on PET/CT approaches for identifying cardiac amyloid deposits and distinguishing diagnostic pathways.
- 18F-flutemetamol tracer evaluation
- 18F-florbetaben PET/CT diagnostic assessment
- Non-invasive diagnosis of AL-CA
The sponsor’s work in this area is directed toward improving the recognition of amyloid involvement in the heart and supporting clearer diagnostic classification across inherited and wild-type disease.
Transthyretin amyloid cardiomyopathy
Another key area is ATTR-CA, including studies that examine functional status and symptom burden in people living with transthyretin-related cardiac disease.
- Exercise capacity
- Quality of life
- Cardiac functional impairment
These investigations reflect interest in the clinical impact of amyloid cardiomyopathy beyond diagnosis, with attention to patient-centred outcomes in chronic heart disease.
Atrial fibrillation and left atrial appendage closure
The sponsor also supports research in atrial fibrillation management, particularly in patients undergoing percutaneous left atrial appendage closure with the Amulet device.
- Antiplatelet therapy
- Thrombotic complications
- Bleeding events
This area focuses on post-procedural cardiovascular care and the balance between protection from thromboembolic risk and avoidance of bleeding harm.
Cardiovascular therapeutics in amyloid heart disease
Clinical interests extend to treatment strategies for amyloid-related heart disease, including therapies used to address symptoms and functional limitation in cardiac amyloidosis.
- Dapagliflozin
- Cardiovascular symptom management
- Functional capacity improvement
The sponsor’s funded studies place emphasis on therapeutic options relevant to patients with progressive infiltrative cardiomyopathy and associated exercise intolerance.
